PTAB shoots down tenth I-MAK Gilead challenge
24-07-2018
PTAB rejects IPR challenges to Gilead patents
14-06-2018
Public interest group challenges ‘unmerited’ Gilead patents
26-10-2017
Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has brought another two patent challenges against Gilead over its hepatitis C medicine sofosbuvir.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Initiative for Medicines, Access & Knowledge, I-MAK, patent, Sovaldi, Gilead, generics, hepatitis C , pharmaceuticals
